openPR Logo
Press release

Anergis Reports Positive Preclinical Proof-of Concept Data of the Second-Generation COP Allergy Vaccine

12-13-2018 12:17 PM CET | Health & Medicine

Press release from: Anergis SA

/ PR Agency: akampion
- The second-generation COP Allergy Vaccines met the preset success criteria: strong TH1 response, absence of IgE response and excellent tolerability
- Anergis will raise new financing to conduct clinical trials with the second-generation COP Allergy Vaccines as soon as possible

EPALINGES, Switzerland, December 13th, 2018 – Anergis, a company developing proprietary ultra-fast Allergy Immunotherapy (AIT), announced today that the Company has successfully completed the mice proof-of-concept study of the second-generation COP allergy vaccines based on its research collaboration with Mymetics SA, a leader in the research and development of virosome-based vaccines. The Company plans to raise new financing to return to clinical trials in allergic patients as soon as possible.

The mice proof-of-concept immunogenicity study evaluated the effects of the Bet v 1 COPs (the birch pollen allergy proprietary peptides) using the five subcutaneous injection schedule used in clinical trials with Anergis’ first-generation product candidate AllerT. The development of AllerT (Bet v 1 COPs plus aluminum hydroxide) was discontinued by Anergis in 2017 following completion of a Phase 2 clinical trial showing evidence of sensitization to the peptides and a 7% reduction in seasonal allergy symptoms vs. placebo (p=0.0047).

In the mice study, AllerT was compared to Bet v 1 COPs linked to Mymetics’ virosomes (the “Bet v 1 COP-virosomes”). As expected, the administration of AllerT led to the development of Bet v 1 specific IgEs (p< 0.001) associated with a more pronounced TH2 than TH1 response. In contrast, in mice receiving the Bet v 1 COP-virosomes, no development of Bet v 1 specific IgEs were observed (p< 0.001 vs AllerT). With the same dose of Bet v 1 COPs, there was a strong boost of immunogenicity with a TH1 antibody response, which was a hundred times greater than with aluminum hydroxide (p< 0.001). The Bet v 1 COP-virosomes were well tolerated.

“We are very satisfied with these new results because we now have a strong data base to expect successful clinical development of our second-generation COP Allergy Vaccines,” said Vincent Charlon, CEO of Anergis. “The new presentation of our peptides ensured a boost in immunogenicity without the development of specific IgEs during treatment. This combination should result in greater efficacy and improved tolerability as compared to the first generation. We will be happy to discuss the results in further detail at the upcoming Biotech Showcase / J.P. Morgan Healthcare Conference in San Francisco in January.”


About Allergies
Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world, affecting over 500 million people. The only curative therapy of allergies available today, known as “desensitization”, “allergy shots” or “allergy immunotherapy”, is the process of inducing tolerance to the allergen. It typically requires at least 3 years of treatment and exposes patients to the risk of serious side effects – in particular immediate (< 30 min) anaphylactic reactions – which can be life-threatening. With its technology, Anergis is shaping the future of allergy treatment by developing therapeutic modalities that will only require 2 months of treatment to obtain a long-lasting reduction of seasonal allergy symptoms.

About Ultra-fast Allergy Immunotherapy Developments by Anergis
Anergis is focusing on novel, proprietary ultra-fast allergy immunotherapies based on Contiguous Overlapping Peptides (COPs). The first-generation against birch pollen allergies, called AllerT, contained three Bet v 1 COPs and aluminum hydroxide as an adjuvant. With AllerT, Anergis established the clinical proof-of-concept of ultra-fast AIT with a single 2-month treatment course by demonstrating 1) rapid and sustained efficacy during two seasons following treatment and 2) four seasons long-term immune memory. Based on a comprehensive clinical data set established over the past years, Anergis initiated a preclinical program with its partner Mymetics SA to test Bet v 1 COP-virosomes as candidates for a second generation of COP allergy vaccines with enhanced efficacy and improved tolerability. The success of this initial proof-of-concept gives Anergis a time-limited option to enter into an exclusive license agreement with Mymetics for the use of virosomes in allergy.

About Anergis
Anergis SA is a Swiss biopharmaceutical company dedicated to the discovery and development of proprietary ultra-fast allergy immunotherapy products for the most prevalent allergies. Anergis was founded by Professor François Spertini, allergist at the University Hospital of Lausanne, Switzerland. Anergis raised over CHF 52 million from private and institutional investors, including BioMedInvest, Sunstone Capital, Renaissance PME and WJFS, Inc. Anergis SA is located in the Biopôle near Lausanne, Switzerland, a life sciences community bringing together industry and academia.

Anergis SA
Biopôle Building SC-A, Route de la Corniche 4
CH-1066 Epalinges, Switzerland
Vincent Charlon CEO,

Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anergis Reports Positive Preclinical Proof-of Concept Data of the Second-Generation COP Allergy Vaccine here

News-ID: 1437435 • Views:

More Releases from Anergis SA

Anergis and Virometix Announce Research Collaboration to Use Synthetic Virus-Lik …
- Study is performed at the Helmholtz Centre for Infection Research and supported by a TRANSVAC2 grant - Epalinges, Switzerland, July 09, 2020 – Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. The study will be conducted at the Helmholtz Centre for

More Releases for COP

"Cop or Drop Forever" Says RogueShot - One Of A Kind
Cop Or Drop Forever: RogueShot Announced 30 Exclusive Products For Each Month Virginia Beach, Virginia - RogueShot has announced to be one of the premium brands rather than casual ones. Keeping the fact in mind that Fashion is not just wearing something, it is about expressing yourself in your way. Being new in the market, we ain't afraid of getting lost in the crowd. Instead, we roar to make the place
Global Mosquito Net Market Forecast 2017-2022: Klamboe, Pyramid, INSECT COP, Mer …
Global Mosquito Net Market Research Report A market study based on the " Mosquito Net Market " across the globe, recently added to the repository of Market Research, is titled ‘Global Mosquito Net Market 2017’. The research report analyses the historical as well as present performance of the worldwide Mosquito Net industry, and makes predictions on the future status of Mosquito Net market on the basis of this analysis. Request For Sample
Global Mosquito Net Market 2017 - Klamboe, Pyramid, INSECT COP, YuanMeng, MENDAL …
The market study, titled Global Mosquito Net Industry 2017, has been compiled by industry experts and is based on a comprehensive analysis of the Mosquito Net market in the world. The geographical distribution and various segments of the Mosquito Net market are extensively studied in this report. The in-depth analysis of the industrial chain supporting the Mosquito Net market in the globe incorporates factual information about every aspect of the market
Global Cyclic Olefin Polymer (COP) Market Analysis, Trend and Forecast to 2021
Market Research Future provides a detailed analysis of 10 years forecast of Cyclic Olefin Polymer market research between 2011 and 2021 and it is expected that Cyclic Olefin Polymer market will register the CAGR of more than 1.25% during the forecast period. Market Highlights: Cyclic Olefin Polymer (COP) also known as Ethylene Copolymer, Clyclon Olefin Copolymer and Ethylene-norbornene Copolymer, is a chemical substance which is precisely used in the manufacturing of
Former Cop Gives Back, Announces New Book
Dothan, AL, USA -- Visit for contact details, review copies, photos, and an author bio. A story of one man's journey to success and how you can live your dreams. ADAM DAVIS, Author of Amazon best-selling devotional, Spirit & Truth: 52 Encouraging Messages for America's Law Enforcement announces the release of his new book, Be Awakened: A New You in 40 Days on January 22, 2017. Davis continues his commitment
NYPD Nudie Cop Puts Clothes On
SOMEWEAR-USA TO LAUNCH NEW LINE AT THE INTERNATIONAL FASHION INDUSTRY CONVENTION Las Vegas, NV - During the week of February 14, 2011, America's hottest new t-shirt experience - Somewear-USA Clothing Company - will reveal it’s 2011 Outrageously Funny T-shirt Line at The MAGIC Marketplace in Las Vegas, Nevada. This is the preeminent trade event in the international fashion industry and will be held The Las Vegas Convention Center & Mandalay Bay